U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286058) titled 'Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis' on Dec. 11.
Brief Summary: Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.
The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.
Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation s...